GlassScriptPhysician profile
Erik V Burton
NPI 1730381179
$154,498.76
in general payments reported to CMS, 2019-2025
46 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $21K · 2021: $7,442 · 2022: $3,029 · 2023: $1,871 · 2024: $1,624 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,012.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $110,433.84 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $17,437.36 | 2019-2024 | Ultomiris, Soliris |
| Emd Serono, INC. | $8,915.39 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $6,641.82 | 2019-2025 | |
| Abbvie INC. | $1,772.32 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $1,154.25 | 2019-2025 | Nuplazid, Daybue |
| Genentech USA, INC. | $856.54 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Amgen INC. | $836.31 | 2019-2025 | Uplizna |
| Biogen, INC. | $780.02 | 2019-2025 | Vumerity, Spinraza, Qalsody |
| Pfizer INC. | $680.08 | 2023-2025 | |
| Horizon Therapeutics Plc | $668.82 | 2022-2023 | Uplizna |
| Allergan, INC. | $535.01 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $342.81 | 2022 | |
| Sk Life Science, INC. | $291.20 | 2021-2025 | Xcopri |
| Celgene Corporation | $265.53 | 2021-2025 | Zeposia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $257.91 | 2019-2025 | Austedo Xr, Ajovy |
| Tg Therapeutics, INC. | $247.53 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $236.02 | 2021 | |
| Ucb, INC. | $231.10 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Sunovion Pharmaceuticals INC. | $219.82 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $217.03 | 2021-2025 | Acthar |
| Acorda Therapeutics, INC | $212.62 | 2019 | |
| Neurelis, INC. | $137.49 | 2020-2023 | Valtoco |
| Ani Pharmaceuticals, INC. | $119.50 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $118.39 | 2019-2025 | Kisunla |
| Livanova USA, INC. | $117.99 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $114.86 | 2024-2025 | |
| Ge Healthcare | $102.82 | 2019 | |
| Merz Pharmaceuticals, LLC | $63.63 | 2025 | Xeomin, Ampyra, Inbrija |
| Neurocrine Biosciences, INC. | $55.59 | 2022-2025 | |
| Lundbeck LLC | $50.98 | 2023 | Vyepti |
| Sumitomo Pharma America, INC. | $49.91 | 2023-2024 | Aptiom |
| Averitas Pharma INC. | $49.05 | 2025 | Qutenza |
| Argenx US, INC. | $43.09 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Greenwich Biosciences, INC. | $41.76 | 2020-2021 | |
| Eisai INC. | $38.78 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $31.23 | 2024 | Rytary |
| Impel Pharmaceuticals INC. | $22.71 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $20.78 | 2025 | Symbravo |
| Sarepta Therapeutics, INC. | $20.39 | 2021 | |
| Tanabe Pharma America, INC. | $16.82 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.78 | 2020 | |
| Ptc Therapeutics, INC. | $12.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.04 | 2022 | |
| Supernus Pharmaceuticals, INC. | $10.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.